Want to see PETS full AI Analyst Report?
Petmed Express (PETS) AI Stock Analysis
Petmed Express
(NASDAQ:PETS)
PETS scores poorly, driven primarily by severely deteriorating fundamentals: a multi-year revenue decline, collapsing margins, large losses, an 80%+ erosion of shareholder equity, and accelerating cash burn with only $13.1M of cash on hand. Technicals reinforce the caution, with the stock trading below all major moving averages and momentum still negative, though deeply oversold readings could support a short-term bounce. Valuation provides no cushion given negative earnings and no dividend. Partially offsetting these risks are a near-debt-free balance sheet, a sharply narrowed quarterly loss, disciplined cost cuts, a growing recurring revenue mix, the pending $37M sale-leaseback, and a fresh leadership and governance refresh. Overall, this remains a high-risk turnaround story where evidence of revenue stabilization and positive cash flow is still needed.
Petmed Express (PETS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $25.80M
- Dividend Yield
- ―
- Average Volume (3M)
- 110.23K
- Price to Earnings (P/E)
- -0.9
- Beta (1Y)
- 1.52
- Revenue Growth
- -19.67%
- EPS Growth
- 34.91%
- Country
- US
- Employees
- 189
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Specialty Retail
Petmed Express Business Overview & Revenue Model
Company Description
PetMed Express, Inc., through its various subsidiaries, operates as a prominent pet pharmacy across the United States. The company provides a comprehensive range of both prescribed and over-the-counter animal medications, health-related items, and ot...
How the Company Makes Money
PetMed Express primarily makes money by selling pet health products directly to consumers through its online storefront and fulfillment operations. The company’s core revenue stream is product sales, including (1) prescription pet medications, where...
Petmed Express Earnings Call Summary
The call presents a cautiously optimistic tone: management reported substantial progress on cost reductions, major technology and operational upgrades (SAP rollout, call center, fraud prevention), improved customer acquisition efficiency (70k new customers; CAC down 15%), higher recurring revenue mix (61.5% of sales), strategic white-label partnership with Rural King, and a sale-leaseback to unlock $37M of real estate value. However, notable challenges remain, including a 19.9% year-over-year revenue decline driven by weaker prescription sales, lower gross profit, an increased adjusted EBITDA loss, and an outstanding unsolicited acquisition proposal. On balance, the operational and financial improvements and strategic initiatives meaningfully outweigh the current headwinds, but execution risk on pending transactions and sustained revenue recovery remain important considerations.
Q1-2027 Updates
Positive Updates
Negative Updates
Company Guidance
Management provided no formal numeric forward guidance but outlined a clear, metric‑driven path to sustainable profitability: they expect benefits from recent tech and operations investments (SAP ERP rolled out in May, new call‑center platform launched in June, Q4 fraud system) and a new freight agreement that can shave up to 2 days off West Coast deliveries to improve retention, while expanding white‑label partnerships (Rural King launched in July across >150 stores in 17 states). Key Q1 metrics they cited as the baseline for this plan include net sales of $41.0M (down 19.9% YoY from $51.2M) — the third consecutive quarter above $40M — gross profit $11.3M (27.6% margin), G&A $11.2M (‑13.5% YoY), advertising $4.2M (‑30.2% YoY), depreciation & amortization $2.1M, net loss $6.1M ($0.28/share) vs a loss of $34.2M ($1.65) a year ago, adjusted EBITDA loss $3.4M, cash $13.1M and no debt, recurring net sales 61.5% of gross (vs 57.6% a year ago), ~70k new customers acquired in Q1 with CAC down 15% to $60 (from $71), and an expected $37M sale‑leaseback of HQ/DC to close in ~120 days under a 10‑year lease to bolster financial flexibility.
Petmed Express Financial Statement Overview
Summary
Financials are in severe distress. Revenue has fallen ~35% since FY2022 (to $179M, with TTM at $169M), gross margin has compressed from ~27.6% to ~22.8%, and the company swung from a $21.1M profit to a $57.3M net loss in FY2026. Operating margin collapsed to -17.5% and EBITDA is deeply negative. Equity has been destroyed, dropping from $142M to just $23M, with ROE at -91.7%. Cash flow is the weakest link: operating cash flow of -$23.8M and free cash flow of -$27.8M (TTM) point to accelerating cash burn. The one meaningful offset is a near-debt-free balance sheet (debt-to-equity of 0.018), which provides limited runway but does not offset material going-concern risk.
Income Statement
8Very NegativeBalance Sheet
22NegativeCash Flow
6Very Negative| Breakdown | TTM | Mar 2026 | Jun 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 168.86M | 179.02M | 226.97M | 274.10M | 256.58M | 273.42M |
| Gross Profit | 40.04M | 40.83M | 69.14M | 77.71M | 71.01M | 75.34M |
| EBITDA | -21.76M | -22.03M | 6.71M | 783.00K | 10.99M | 29.81M |
| Net Income | -29.28M | -57.29M | -6.27M | -7.46M | 5.14M | 21.10M |
Balance Sheet | ||||||
| Total Assets | 63.76M | 81.19M | 148.70M | 169.88M | 170.00M | 176.32M |
| Cash, Cash Equivalents and Short-Term Investments | 13.08M | 21.41M | 54.72M | 55.30M | 104.09M | 111.08M |
| Total Debt | 414.00K | 535.00K | 996.00K | 1.45M | 995.00K | 0 |
| Total Liabilities | 40.77M | 52.25M | 63.57M | 73.15M | 60.04M | 34.13M |
| Stockholders Equity | 22.99M | 28.94M | 85.13M | 96.73M | 109.97M | 142.19M |
Cash Flow | ||||||
| Free Cash Flow | -27.77M | -33.01M | -395.00K | -194.00K | 22.54M | 16.75M |
| Operating Cash Flow | -23.81M | -28.39M | 4.72M | 4.32M | 27.80M | 18.50M |
| Investing Cash Flow | -3.96M | -4.62M | -5.11M | -40.67M | -10.26M | -1.75M |
| Financing Cash Flow | -274.00K | -299.00K | -181.00K | -12.44M | -24.54M | -24.38M |
Petmed Express Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PETS, the sentiment is Negative. The current price of 1.21 is below the 20-day moving average (MA) of 1.22, below the 50-day MA of 1.48, and below the 200-day MA of 2.11, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 33.80 is Neutral, neither overbought nor oversold. The STOCH value of 31.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PETS.
Petmed Express Risk Analysis
Petmed Express disclosed 36 risk factors in its most recent earnings report. Petmed Express reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksPetmed Express Peers Comparison
Overall Rating
CHWY66Neutral
TSCO60Neutral
WOOF59Neutral
BARK43Neutral- PETS43Neutral
BQ42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CHWY | 66Neutral | $8.56B | 32.26 | 62.13% | ― | 5.86% | 81.66% |
| TSCO | 60Neutral | $17.68B | 18.25 | 37.64% | 2.80% | 3.53% | -10.44% |
| WOOF | 59Neutral | $747.56M | 23.58 | 2.58% | ― | -1.32% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BARK | 43Neutral | $72.27M | -2.22 | -39.54% | ― | -21.25% | -5.40% |
| PETS | 43Neutral | $25.80M | -0.86 | -91.67% | ― | -19.67% | 34.91% |
| BQ | 42Neutral | $3.77M | -1.25 | -2.77% | ― | -8.84% | 8.50% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PETS | Petmed Express | 1.19 | -1.28 | -51.82% | |
| TSCO | Tractor Supply Company | 33.94 | -17.86 | -34.48% | |
| CHWY | Chewy Inc | 21.29 | -12.50 | -36.99% | |
| BQ | Boqii Holding Limited | 0.48 | -2.67 | -84.83% | |
| BARK | BARK Inc Class A | 8.00 | -8.04 | -50.14% | |
| WOOF | Petco Health And Wellness Company Inc | 2.61 | -0.50 | -16.08% |
Petmed Express Corporate Events
PetMed Express Amends Plan for New CEO Equity Awards
PositiveOn September 27, 2026, PetMed Express, Inc. amended its 2024 Inducement Incentive Plan to increase the shares reserved for issuance by 500,000, bringing the total to 850,000 shares. The change preserves all other terms of the plan, which remains clos...
PetMed Express adds human capital expert to board
PositiveOn September 17, 2026, PetMed Express expanded its board to five directors by appointing human capital expert Tamar Elkeles as an independent director and Chair of the Compensation and Human Capital Committee. Announced on September 21, 2026, her rol...
PetMed Express Names Jeff Willard CEO Amid Transformation
PositivePetMed Express announced on September 17, 2026, that its board has appointed consumer and ecommerce veteran Jeff Willard as Chief Executive Officer, President, and director, effective September 28, 2026, succeeding Leslie C.G. Campbell, who has serve...
PetMed Express Shareholders Expand Incentive Plan And Governance
PositiveOn August 11, 2026, PetMed Express shareholders approved an amendment to the company’s 2024 Omnibus Incentive Plan to increase the shares of common stock reserved for issuance by 1,800,000, expanding the equity pool available for employee and d...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 28, 2026